Profile

Business Description

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.

Company Info

Address:
1860 Montreal Rd.
Tucker, GA 30084 US

Telephone:
678-892-8800

Fax:
404-601-1431

Email:
info@cocrystalpharma.com

Industry Classifications

NAICS:
Research and Development in Biotechnology (541711)

SIC:
Commercial Physical and Biological Research (8731)

ICB:
Biotechnology (4573)

GICS:
Pharmaceutical, Biotechnology & Life Sciences (3520)